Peptide and Oligonucleotide CDMO Market to Triple by 2033 Reaching $8.14 Billion: Analysis by Product, Service, End-Use and Region Featuring Solvay, Ensinger, 3DXTech and More - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Peptide and Oligonucleotide CDMO Market Forecast to 2033" has been added to ResearchAndMarkets.com's offering.

The global peptide and oligonucleotide CDMO market is witnessing robust growth, with its valuation projected to leap from USD 2.80 billion in 2024 to USD 8.14 billion by 2033, achieving a CAGR of 12.75% from 2025 to 2033. This growth is attributed to the escalating demand for complex and targeted therapeutics, the surge in investments in biologics and nucleic acid-based drug development, the growing trend of outsourcing among pharmaceutical and biopharmaceutical firms, and advancements in the synthesis and delivery technologies for peptides and oligonucleotides.

Advances in peptide synthesis, synthetic chemistry, and oligonucleotide manufacturing have simplified the production and design of complex molecules, enhancing their therapeutic applications. This evolution has fueled the demand for contract development and manufacturing organizations (CDMOs) equipped with specialized expertise in these domains.

The shift towards personalized medicine has intensified the need for tailored peptide and oligonucleotide therapies, further boosting the role of CDMOs in the production and development of these personalized therapies. Regulatory bodies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have been instrumental in shaping guidelines for the manufacturing and development of oligonucleotides and peptides. These developments have, in turn, opened lucrative growth avenues for the market.

Global Peptide and Oligonucleotide CDMO Market Report Segmentation

This report provides thorough revenue growth forecasts across global, regional, and country levels, offering a deep dive into the latest industry trends within various sub-segments from 2021 to 2033. It segments the global peptide and oligonucleotide CDMO market based on product, service, end use, and region.

Product Outlook (Revenue, USD Million, 2021-2033)

• Peptides
• Oligonucleotides

Service Outlook (Revenue, USD Million, 2021-2033)

• Contract Development
• Contract Manufacturing

End Use Outlook (Revenue, USD Million, 2021-2033)

• Pharmaceutical Companies
• Biopharmaceutical Companies
• Others

Regional Outlook (Revenue, USD Million, 2021-2033)

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa (MEA)

Why You Should Buy This Report

• Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
• Competitive Landscape: Explore the market presence of key players.
• Future Trends: Discover pivotal trends and drivers shaping the market's future.
• Actionable Recommendations: Leverage insights to identify new revenue streams and guide strategic decisions.

Report Deliverables

• Market intelligence for effective decision-making
• Market estimates and forecasts from 2018 to 2030
• Growth opportunities and trend analyses
• Segment and regional revenue forecasts for market assessments
• Competition strategy and market share analysis
• Product innovation listings to keep you ahead of the curve

Key Attributes

The companies profiled in this Peptide and Oligonucleotide CDMO market report include:

• Solvay
• Ensinger
• 3DXTech
• Essentium
• ARMOR GROUP
• IEMAI 3D
• Shandong Kaisheng New Materials Co., Ltd.
• Lehmann & Voss
• INTAMSYS Technology Co. Ltd.
• DELRAY Systems

For more information about this report visit https://www.researchandmarkets.com/r/13b5as

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900